Why do some people enjoy robust health far into old age, while others encounter serious disease decades earlier?
This question, at the heart of human ageing research, has sparked curiosity for generations.
Recent findings, presented at the European Society of Human Genetics annual conference in Gothenburg, offer a modern twist on an age-old puzzle.
The emerging answer may reside not in singular individuals, but within families whose members consistently reach advanced ages with minimal illness.
The world’s population is ageing rapidly. Life expectancy across much of the globe has soared over the last two centuries. In many countries, it is now common for people to live beyond eighty or even ninety years.
Yet these extra years often fail to deliver sustained health. While we are living longer, our healthspan—the period free from serious disease—remains stubbornly short for many. Chronic illness, disability and frailty still cloud the later years of life for millions.
One group of researchers at Leiden University Medical Center in the Netherlands has shifted focus from individuals to families. The team leveraged the extensive Leiden Longevity Study, which tracks families where exceptional old age clusters together. This approach recognises that shared biology can reveal secrets to healthy ageing more reliably than isolated cases. It also sidesteps the confounding effects of lifestyle, environment and luck. The results are striking.
Researchers discovered that middle-aged offspring of long-lived parents developed cardiometabolic diseases an average of 13 years later than their peers with shorter-lived parents. This difference was not trivial. Cardiometabolic diseases—such as type 2 diabetes, high blood pressure and heart attacks—are major causes of illness and death worldwide. A 13-year delay represents a dramatic extension of healthspan.
The quest did not end there. Scientists scanned the genomes of 212 sibling groups from long-lived families. By comparing genetic code across these individuals, they identified four key regions likely to contain longevity-related genes.
This clever narrowing meant focusing on about 350 genes rather than examining all 20,000-plus human genes. Further analysis revealed twelve rare gene variants that change the structure of proteins in ways that might influence lifespan.
Among these rare variants, one stood out: a change in the CGAS gene. This gene is known for its role in detecting misplaced DNA within cells and triggering an immune response, especially during viral infections or when cells are damaged. Researchers found this variant in two long-lived families, suggesting it may play an important role in promoting a longer healthspan.
How does this work? CGAS regulates inflammation. Inflammation is a double-edged sword—a vital line of defence against infection and injury but damaging if chronically activated.
Persistent inflammation is a hallmark of ageing and has been tied to diabetes, heart disease, dementia and cancer. The CGAS variant may dampen this response just enough to reduce tissue damage without compromising the body’s ability to fight infection. Members of these families may have one less active copy of the gene, resulting in a more controlled response to cellular stress.
Early laboratory experiments support this theory. Researchers observed a pronounced effect in cells carrying the CGAS mutation, inflammation markers decreased significantly. These findings provide a tantalising clue that reducing chronic inflammation could extend healthspan.
The next step involves animal studies using killifish—a small vertebrate with a natural lifespan of only three to nine months—at the Max Planck Institute for the Biology of Ageing in Germany. By introducing the CGAS mutation into killifish, scientists can rapidly assess its impact on both lifespan and health.
The implications are profound. If similar mechanisms operate in humans, targeting inflammation through pathways like CGAS could delay multiple age-related diseases simultaneously. Unlike treating individual conditions one by one, this strategy aims to address their shared biological roots.
Experts caution that context is everything. The immune system is finely balanced. Too little activation can leave the body open to infection or cancer; too much can lead to destructive inflammation and autoimmunity. Complete suppression of CGAS is risky—moderation is key. Animal studies will clarify whether tweaking this pathway can safely lengthen healthspan.
Importantly, these findings underscore the value of family-based research designs. Studying single individuals can be misleading because lifestyle factors—diet, exercise, education—often overshadow genetic signals. Family studies help untangle these influences by revealing inherited patterns across generations.
Genetics, however, is not destiny. While rare variants can provide protection, they are not guarantees of long life or robust health. Environmental factors, medical care, and personal choices remain crucial. Many people with “average” genetics still live long, healthy lives through prudent habits and good fortune.
The study also highlights the limitations of direct-to-consumer genetic testing for longevity prediction. Most people carry a mix of genetic strengths and weaknesses—there is no single “longevity gene”. The story is complex, woven from thousands of small effects and rare family-specific changes like those seen in the Leiden study.
This research sits at the intersection of biology, medicine and public health policy—and it could reshape how we think about ageing. What if we could slow ageing at its source? Targeting fundamental processes like inflammation could push back the onset of many chronic diseases together, not just delay one while another appears sooner after.
The potential benefits are enormous—not just for individuals but for societies facing ballooning healthcare costs from an ageing population. Longer healthspan means more years free from dependency and disability, less strain on health systems and social care networks, and greater economic productivity from older adults.
The researchers behind this work plan to explore other promising gene variants uncovered in their study by collaborating with scientific teams worldwide. Each discovery adds another piece to the puzzle of healthy ageing and moving us closer to personalised interventions based on genetic risk profiles.
The European Society of Human Genetics describes these findings as a leap forward in understanding how biology shapes longevity and healthspan. They offer hope that future generations might enjoy not just longer lives but better ones, years filled with activity, independence and meaning instead of illness and decline.
Yet challenges remain. Translating laboratory discoveries into safe therapies takes time and rigorous testing. Animal studies come next; then careful human trials must follow before any intervention reaches the clinic.
In parallel, public health must continue promoting proven strategies, balanced diets rich in vegetables and fibre; regular physical activity; managing blood pressure, cholesterol, and blood sugar; not smoking; staying socially engaged; and maintaining mental stimulation and emotional well-being.
The secret to a long healthy life may be part luck, part lifestyle, part family inheritance—a complex interplay scientists are only beginning to decipher. But each new insight brings us closer to treatments that could shift society’s experience of old age from inevitable decline to vibrant longevity.
The search goes on, fuelled by curiosity and compassion—and by families whose remarkable stories illuminate what is possible when biology and circumstance align just right.
As research continues and new data emerges, one message remains clear. Longevity science is no longer science fiction. It is becoming a practical reality with growing relevance for everyone who hopes to add not just years to life but life to years.
The post Cardiometabolic Disease May Be Delayed in Children of Long-Lived Parents first appeared on PP Health Malaysia.
